Overview

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide corresponding to residues 147–161 of a protein isolated from human gastric juice. It has been the subject of extensive preclinical investigation across a range of tissue-injury models — musculoskeletal, gastrointestinal, cardiovascular, and neurological — over three decades of research primarily from Sikirić and colleagues at the University of Zagreb.

Almost all published work on BPC-157 is preclinical. Rigorous human clinical trials in the injuries and conditions where it is most frequently discussed (tendinopathy, inflammatory bowel disease, muscle tears) have not been published as of this writing.

Mechanism (as reported in the literature)

Studies indicate BPC-157 acts through several convergent pathways:

  • Angiogenic response. Multiple animal models report upregulation of vascular endothelial growth factor receptor 2 (VEGFR2) and formation of new capillary networks in injured tissue.
  • Nitric-oxide (NO) system modulation. Research suggests BPC-157 interacts with the NO pathway; some of its cytoprotective effects in the GI tract are attenuated by NO synthase inhibitors and modulated by L-arginine or L-NAME co-administration.
  • Growth-factor and receptor expression. Animal studies report increased fibroblast growth factor, transforming growth factor β, and early growth response gene 1 expression at injury sites.
  • Neurotransmitter-system effects. Preclinical work describes modulation of dopaminergic, serotonergic, and GABAergic systems, though the clinical significance in humans is unstudied.

Research findings

  • Tendon and ligament models. Rat studies of Achilles-tendon transection and medial collateral-ligament injury report accelerated healing, increased tendon-cell outgrowth, and improved biomechanical outcomes in BPC-157-treated animals (e.g., Chang et al., 2011; PMID 21316489; Krivic et al., 2006).
  • Gut-barrier and IBD models. Animal studies of induced colitis, gastric ulceration, and short-bowel syndrome report protective effects on mucosal integrity and reduced lesion size (Sikirić et al., long-running series).
  • Muscle-injury models. Rat crush-injury and denervation-atrophy models report accelerated functional and histological recovery.
  • Cardiovascular models. Preclinical studies describe protective effects in isoprenaline-induced cardiotoxicity, thrombosis, and hyperkalemia models.

The consistency across models is notable; the absence of large randomised human trials is equally notable.

Common dosing (animal studies)

Preclinical work most commonly reports doses in the range of 10 µg/kg/day in rats, which — while not directly translatable — is often used as a reference point in the broader literature. Reported human self-experimentation ranges in the community fall roughly between 200 and 500 mcg per administration, once or twice daily. These are ranges reported in the literature and community writeups, not recommendations.

Both subcutaneous (typically local to the injury site) and oral routes appear in animal studies. Oral bioavailability of the parent peptide is uncertain; some researchers argue for a stable gastric pentadecapeptide effect.

Reconstitution

A common reconstitution reported in the literature is 5 mg of lyophilised peptide in 2 mL bacteriostatic water, producing a 2,500 mcg/mL solution. At this concentration, a 250 mcg research dose corresponds to 0.1 mL, or 10 units on a U-100 insulin syringe.

Use the calculator below to model any vial/volume combination.

Storage

Lyophilised BPC-157 is generally reported as stable at room temperature for shipping and for short periods. Once reconstituted, the peptide is typically stored refrigerated at 2–8 °C and used within 30 days; longer storage is done frozen. Repeated freeze-thaw cycles should be avoided.

  • TB-500 — often discussed alongside BPC-157 in tissue-recovery contexts.

Common stacks

References

  • Chang, C.-H., et al. (2011). “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of Applied Physiology, 110(3). PMID 21316489.
  • Krivic, A., et al. (2006). “Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation.” Journal of Orthopaedic Research, 24(5). PMID 16583442.
  • Sikirić, P., et al. (2013). “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Current Pharmaceutical Design, 19(1). PMID 22950504.
  • Sikirić, P., et al. (2020). “Stable gastric pentadecapeptide BPC 157 as a therapy against various vascular occlusions.” Current Neuropharmacology, 18(11). PMID 32669064.